Clinical Trial Update: Atomoxetine in Melanocortin Obesity Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating atomoxetine for Melanocortin Obesity Syndrome (MCOS) is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanocortin Obesity Syndrome

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Melanocortin Obesity Syndrome, MCOS | Phase 2 | Status: NOT_YET_RECRUITING